Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?
December 22, 2010
Will Genentech Embrace PGx in Appeal of FDA Decision to Revoke Approval of Avastin in Breast Cancer?
In recommending the removal of the breast cancer indication from Avastin's label, the FDA urged Genentech "to conduct additional research to identify if there may be select groups of patients who might benefit from this drug."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - NCI's Proposed IP Policy May Hinder Personalized Medicine, Stakeholders Say
August 25, 2010 / Pharmacogenomics Reporter - Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 1, 2012 / Pharmacogenomics Reporter - 'Middle Ground' Avastin Proposal Could Maintain Access for Molecularly Defined Breast Cancer Patients
August 17, 2011 / Pharmacogenomics Reporter - Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
March 2, 2011 / Pharmacogenomics Reporter